Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS: Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [766]
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [18]
In the citing paper
“Semaglutide by subcutaneous injection was shown to be superior to exenatide once weekly, dulaglutide, and liraglutide in lowering HbA1c.19”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [19]
In the citing paper
“Serum calcitonin was measured during these trials, and no notable difference in mean levels was seen between the treatment arms.”
From Safety of Semaglutide (2021) · cites this paper as [22]
In the citing paper
“None of these were medullary carcinoma.”
From Safety of Semaglutide (2021) · cites this paper as [22]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 RAs also reduce body weight by inducing feelings of satiety and fullness and reducing feelings of hunger, thereby lowering energy intake (3,4).”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“mology to native human GLP-1 and is structurally similar to liraglutide (10), but important structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and increase its specific high-affinity binding to albumin (10).”
BackgroundDeclaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Cited by
Items 501–600 of 657
Swift, C., Frazer, M., Sargent, A., Leszko, M., Buysman, E. K., Gronroos, N. N., Alvarez, S., Dunn, T. J., & Noone, J. M. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.12.014 · Cited by 2
Rosenstock, J., Cariou, B., Eliasson, J., Frappin, G., Kaltoft, M. S., Montanya, E., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15339 · Cited by 2
Matovinović, M., Belančić, A., Jug, J., Mustač, F., Sirovica, M., Santini, M., Bošnjaković, A., Lovrić, M., & Benčić, M. L. (2024) · Diabetology · doi:10.3390/diabetology5010003 · Cited by 2
Semaglutide: A revolution in the treatment of obesity and prevention of cardiovascular disease
Bilska, W., Żydek, A., Ciułek, U., Paduch-Jakubczyk, W., Dubińska, M., Zduńczyk, W., & Dobosz, A. (2024) · Quality in Sport · doi:10.12775/qs.2024.22.55010 · Cited by 2
Islam, Q. T., Zaman, M. S., & Hasan, M. J. (2024) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v53i3.75561 · Cited by 2
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis
Bandyopadhyay, I., Dave, S., Rai, A., Nampoothiri, M., Chamallamudi, M. R., & Kumar, N. (2021) · Current Drug Targets · doi:10.2174/1389450122666210901125420 · Cited by 2
Serpa-Díaz, D., Llanos-Florez, C. A., Uribe, R. A. S., Molina, D. I., Giraldo, G. C., Urina‐Triana, M., Suarez-Rodriguez, A. F., & Alzate-Vinasco, M. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01586-7 · Cited by 2
Newer Outpatient Diabetes Therapies and Technologies
Kamal, N., Lee, K., & Aleppo, G. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.002 · Cited by 2
SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide
Shirakawa, J., & Terauchi, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.01.35 · Cited by 2
Rubio-Almanza, M. (2019) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14103.2019.664939 · Cited by 2
Drug depots for obesity targeting metabolism, appetite, and inflammation
Fayyaz, M., & Smith, A. M. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2554718 · Cited by 2
Ризвановна, А. М., & Zhernakova, J. (2021) · Systemic Hypertension · doi:10.26442/2075082x.2021.4.201305 · Cited by 1
Lozano, F. P., Marcos, A. R., Fernández, R. C., Rodrigo, A. B., Martínez‐Hervás, S., & Ampudia‐Blasco, F. J. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501574 · Cited by 1
Cavalcante, B., Lins, F. S. V., Coelho, C. I. H. M., & Galvão, J. G. F. M. (2025) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.61164/rmnm.v9i1.3948 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Popoviciu, M. S., Reurean‐Pintilei, D., Salmen, T., Rus, M., Ferician, A. C., Sava, C. N., Ardelean, A. I., Moroianu, L.-A., & Stoian, A. P. (2025) · Biomedicines · doi:10.3390/biomedicines13092174 · Cited by 1
Glycemic and Weight Outcomes with Semaglutide in Middle Eastern Patients with Type 2 Diabetes
Ahmed, F., Merghani, T. H., Altair, Y., Qashlan, A., Parsad, H., Hamad, F., Alnahdi, A., AlShehhi, A., Bakhiet, F., Ali, H., et al. (2025) · Clinical Diabetology · doi:10.5603/cd.106464 · Cited by 1
Mahmoud, M. R., Shahien, M. M., Tufaif, H. A. A., Saâdi, H., Khatoon, F., & Abdelaziz, A. G. (2025) · Journal of Pioneering Medical Science · doi:10.47310/jpms2025140916 · Cited by 1
The Art and Science of Antidiabetic Medications and Obesity Management
Sawhney, S. K., Kapri, A., Chaudhary, G., & Chauhan, B. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575413887251001111806 · Cited by 1
Chan, Y.-C., Chuang, S., Wu, L.-C., Kuo, Y., Lian, Y.-Z., & Chen, Y. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.11.036 · Cited by 1
Ma, Z., Lin, Z., Wang, Z., Wu, H., & Dong, Y. (2025) · Asian Heart Journal · doi:10.1097/ah9.0000000000000024 · Cited by 1
Robinson, K. M., Rodriguez, S. A., Pedagarla, C., Eyck, P. T., Correia, M. L., & Dokun, A. O. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70114 · Cited by 1
Semaglutide Hype or Hope: Evidence-based Review in Diabesity
Gupta, S., Makkar, B. M., Kesavadev, J., & Kumar, A. M. V. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1439 · Cited by 1
Wang, S., Hu, P., Shen, Z., & Chen, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01848-6 · Cited by 1
Sato, G. E., Uchino, H., Takuma, K., Saito, M., Fuchigami, A., Iwata, Y., Yoshikawa, F., & Hirose, T. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01864-6 · Cited by 1
Jabeen, M., Raja, U. Y., Ishtiaq, O., & Farooq, I. (2026) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.23206 · Cited by 1
Jin, P., Ji, L., HUANG, Y., Ding, H., Xie, D., Jiang, X., Yuan, X., Cao, Z., Zhang, H., & Yuan, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70849 · Cited by 1
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Khan, S. M., Khan, M. S., Arumugam, A., Biswas, M., Saini, A. K., & Kollipara, S. (2026) · Journal of Clinical and Translational Research · doi:10.36922/jctr026250056 · Cited by 1
Murthy, S. S., Shah, D., Shejole, V. S., Sahay, R. K., Maheswari, S., Rao, V., Giri, R., Mehar, D., Agarwal, D., Sailaja, B., et al. (2026) · Journal of diabetology research. · doi:10.52338/jodr.2026.5831 · Cited by 1
Ortiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Les traitements médicamenteux de l’obésité
Rives‐Lange, C., Boudaoud, A. A., Czernichow, S., & Carette, C. (2017) · Acta Endoscopica · doi:10.1007/s10190-017-0636-3 · Cited by 1
Scherbaum, W. A., & Hamann, A. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0356-5 · Cited by 1
Fricke, U., Hein, L., & Schwabe, U. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_3 · Cited by 1
Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report
Alsifri, S. N., Elbadawi, H., Alsabaan, F., Almahfouz, A., Alyahya, K. A., Shesha, E., Esba, L. C. A., Alnais, M., Aldahash, R., Alharbi, T., et al. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.131002 · Cited by 1
New drug: Semaglutide for type 2 diabetes
(2020) · Australian Prescriber · doi:10.18773/austprescr.2020.046 · Cited by 1
and, C. R., & Petrie, J. R. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch6 · Cited by 1
Fasting period after Rybelsus administration influences clinical benefit
Bando, H., Hayashi, K., Miki, K., Yasuoka, E., Kamoto, A., & Yasuoka, T. (2022) · International Journal of Complementary & Alternative Medicine · doi:10.15406/ijcam.2022.15.00603 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
The Weight Loss Effects of Popular Anti-diabetic Medications: A Literature Review
Ahmed, N. S. I., & Alsayed, N. (2024) · Studies in systems, decision and control · doi:10.1007/978-3-031-62102-4_74 · Cited by 1
Zhang, K., Zhao, A., Wang, Z., Ye, K., Xu, Z., Gong, X., & Zhu, G. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01449-1 · Cited by 1
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II
Siamashvili, M., & Davis, S. N. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436593 · Cited by 1
Gæde, P., Johansen, P., Tikkanen, C. K., Pollock, R. F., Hunt, B., & Malkin, S. J. P. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0638-y · Cited by 1
Johansen, P., Hunt, B., Iyer, N. N., Dang‐Tan, T., & Pollock, R. F. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00945-2 · Cited by 1
Zhang, X.-H., Wu, A.-X., Yang, Z., Sun, K.-W., Yang, T., Wang, N.-S., & Zhang, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3256039/v1 · Cited by 1
Anyiam, O. (2025) · Nottingham ePrints (University of Nottingham) · Cited by 1
Novos antidiabéticos: para além do efeito hipoglicemiante
Carmo, F. S. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/kdaq-px25
Diabetic Pharmacotherapies in Kidney Disease
Chon, D. A., Oxman, R. T., MULLUR, R. S., & Weinreb, J. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_5
GLP-1 Obesity and Diabetes Gerald H Tomkin and Daphne Owens
TOMKIN, G. H. (2019) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2019.03.000553
SUSTAIN program: klinikai eredmények
Balogh, Z. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.s2.2
Los arGLP1: una oportunidad para el tratamiento del riesgo cardiometabólico
Miramontes‐González, J. P. (2021) · doi:10.52102/contexto_epidemiologico/art-3
Incretin‐Based Therapy for the Management of Type 2 Diabetes
Gonzales, K., & Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch12
Once weekly semaglutide for treatment of obesity
Mikhail, N. E. (2021) · Journal of Clinical and Laboratory Research · doi:10.31579/2768-0487/015
Frare, P. (2004)
Proceedings of the IV International Conference on Obesity and Chronic Diseases (ICOCD-2019)
(2019) · Journal of Obesity and Chronic Diseases · doi:10.17756/jocd.2019-suppl1
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2021) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20210604.17
La primera impresión no es la que cuenta
Cepeda, R. M. A. V., & Martín, F. J. C. (2022) · Diabetes práctica · doi:10.52102/diabet/pract/2022.1/art4
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Investigating Semaglutide in Adult Patients on Body Weight Compared with Other GLP-1 Drugs
Farrash, S., Aleisa, L., Alhazmi, N. Z., Almatrafi, N., Alharbi, T., Kelantan, S., Alotaibi, L., Hunaydi, W., Alnimari, S., Alqarni, N., et al. (2023) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/j9zsdr5dno
Review of Efficacy and Safety of Semaglutide in the Management of Obesity
Han, S., & Park, T. E. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.1.1
Singh, A. K., & Chawla, R. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01337-1
Causal network perturbation analysis identifies known and novel type-2 diabetes driver genesPreprint
Zhao, Y., Taha, H. B., Ansarullah, Qian, K., Kumar, P., Mahoney, J. M., He, H., George, J., & Li, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.22.595431
Semaglutide in the Treatment of Diabetes and Associated Obesity
Makuch, R., Chrościcka, A., Gała, K., Czajka, A., Lenard, P., Kucharski, A., Michalska, S., Pilarski, K., Dewicka, M., & Wawrzyniak, A. M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.73.51699
Chacon, A. N., Su, W., Hou, T., Guo, Z., & Gong, M. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.02.601700
Semaglutide For Weight Loss: A Literature Review
Sadana, F. C., & Laksemi, D. A. A. S. (2024) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.5.0724.1908
Managing heart failure in the longer term
Ahmed, F. Z., Beezer, J., Fuat, A., Halliday, B. P., Ludman, A. J., Pellicori, P., Savage, H. O., Taylor, C. J., & Cleland, J. G. F. (2024) · Considerations in Medicine · doi:10.1136/conmed-2024-000013
The Future of Alcohol Use Disorder Treatment and Research
Srivastava, A. B., & Wai, J. M. (2024) · Psychiatry update · doi:10.1007/978-3-031-73553-0_15
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Self-citationSind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
GLP-1 receptor agonists – an evolving paradigm in perioperative medication management
Lim, E., Szental, J., & Hamblin, S. (2025) · Australian and New Zealand College of Anaesthetists eBooks · doi:10.60115/11055/1303
Lozano, F. P., Marcos, A. R., Fernández, R. C., Rodrigo, A. B., Martínez‐Hervás, S., & Ampudia‐Blasco, F. J. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501574
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Nakagawa, T., Nakamura, Y., Kubo, Y., Tsunemi, S., Tsukiyama, H., Kano, M., Yokota, K., & Sone, M. (2025) · Journal of St Marianna University · doi:10.17264/stmarieng.16.13
The Emergence of Bioactive Peptides as Anti-diabetic Agents: A Review
Prajapati, R., Singh, R. M., Singh, V., & Katrolia, A. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037386831250806112604 · Cited by 1
An updated patent review of small molecule glucagon receptor antagonists (2020–2024)
Wang, C., Lyu, L., Liu, D., & Yuanjia, H. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2559928
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Xu, Y., Ji, G., Shi, C., Tan, Y., Wang, L., & Gui, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112954
GLP-1 receptor agonists – an evolving paradigm in perioperative medication management
Lim, E., Szental, J., & Hamblin, S. (2025) · Australasian anaesthesia · doi:10.60115/11055/1383
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Pavlova, M. G. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-475
Bennett, K. A., Gouleguine, R., Sutherland, C. D., & Savage, A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117575
Deng, Z., Zheng, D., Son, J., Du, W. J., McKimpson, W. M., Liu, Q., & Accili, D. (2025) · Acta Physiologica · doi:10.1111/apha.70141
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031555
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031567
Self-citationLyseng-Williamson, K. A. (2020) · Figshare · doi:10.6084/m9.figshare.11788875
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031546
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031564
Self-citationLyseng-Williamson, K. A. (2020) · Figshare · doi:10.6084/m9.figshare.11788854
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031558
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031549
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031561
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031552
Self-citation
Metadata
- Authors
- Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R.
- Affiliations
- Oregon Health & Science University (US)
- Rotherham Institute for Obesity, Clifton Medical Centre, Rotherham, U.K.
- Centre Hospitalier Sud Francilien (FR)
- University of Siena (IT)
- GWT-TUD GmbH (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Inc., Plainsboro, NJ
- MedStar Health Research Institute (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-15
- Volume
- 41
- Issue
- 2
- Pages
- 258-266
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2774157762
- Cited by
- 596
- References
- 32
- Citations by year
- 2026: 57 · 2025: 91 · 2024: 88 · 2023: 68 · 2022: 68 · 2021: 48 · 2020: 64 · 2019: 55 · 2018: 51 · 2017: 3
- FWCI
- 37.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, exenatide extended-release, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, injection site reactions, non-inferiority, oral antidiabetic drugs, drug safety and efficacy comparison, weekly dosing
- MeSH terms
- Exenatide, Semaglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.